RxDoctor Payments Data

Julie Drolet, MD

Urogynecology and Reconstructive Pelvic Surgery · York, PANPI 1841286242

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,950 of the $28,726 with a category attached, or 69.4%. AbbVie accounts for 93.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $26,048 and has fallen 99.9% since, to $35 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,726in general payments, 2019–2025

Across 84 payments — averaging $341.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Axonics, Inc.$713
  • Applied Medical Resources Corporation$648
  • Hologic Sales And Service, LLC$101
  • Caldera Medical, Inc$51
  • Bluewind Medical$42
  • plus $189 from 8 others

What the payments were for

  • Speaking & faculty fees$19,95069%
  • Travel & lodging$6,42522%
  • Food & beverage$2,2668%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,726 in reported general payments places this provider in the 90th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$222,024
Medicare patients
380
Services billed
1,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron104$74,309
GemtesaVibegron80$50,231
Estradiol303$19,995
Methenamine Hippurate284$12,118
Mirabegron ErMirabegron31$11,083
Solifenacin Succinate74$5,222
Trospium Chloride ErTrospium Chloride24$3,591
Darifenacin ErDarifenacin Hydrobromide25$3,444
Trimethoprim76$3,371
Trospium Chloride123$2,800
Clobetasol Propionate34$1,937
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst152$1,162
Estradiol (Once Weekly)Estradiol15$859
Minocycline Hcl42$815
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav54$667

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →